[go: up one dir, main page]

AR054739A1 - Composicion de liberacion sostenida de droga proteica - Google Patents

Composicion de liberacion sostenida de droga proteica

Info

Publication number
AR054739A1
AR054739A1 ARP060100600A ARP060100600A AR054739A1 AR 054739 A1 AR054739 A1 AR 054739A1 AR P060100600 A ARP060100600 A AR P060100600A AR P060100600 A ARP060100600 A AR P060100600A AR 054739 A1 AR054739 A1 AR 054739A1
Authority
AR
Argentina
Prior art keywords
sustained release
release composition
drug sustained
proteic
carrier substrate
Prior art date
Application number
ARP060100600A
Other languages
English (en)
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR054739A1 publication Critical patent/AR054739A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion de liberacion sostenida de una droga proteica. La composicion comprende un sustrato portador y una droga proteica incorporada en el sustrato portador. El sustrato portador consiste esencialmente de un ácido hialuronico y sus sales, un aminoácido, y un oxido de polialquilo.
ARP060100600A 2005-02-21 2006-02-20 Composicion de liberacion sostenida de droga proteica AR054739A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050014051 2005-02-21

Publications (1)

Publication Number Publication Date
AR054739A1 true AR054739A1 (es) 2007-07-11

Family

ID=36916702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100600A AR054739A1 (es) 2005-02-21 2006-02-20 Composicion de liberacion sostenida de droga proteica

Country Status (16)

Country Link
US (1) US8025900B2 (es)
EP (1) EP1850875A4 (es)
JP (1) JP2008530204A (es)
KR (1) KR100815114B1 (es)
CN (1) CN101123988A (es)
AR (1) AR054739A1 (es)
AU (1) AU2006214913A1 (es)
BR (1) BRPI0607000A2 (es)
CA (1) CA2595581A1 (es)
IL (1) IL184558A0 (es)
MX (1) MX2007010131A (es)
MY (1) MY139088A (es)
NZ (1) NZ556584A (es)
TW (1) TW200640492A (es)
WO (1) WO2006088336A1 (es)
ZA (1) ZA200705533B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
DE102006030164A1 (de) * 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
KR100939983B1 (ko) * 2006-10-31 2010-02-03 주식회사 엘지생명과학 히아루론산-소수성 폴리 아미노산 공중합체
CN102014873A (zh) * 2008-02-25 2011-04-13 诺瓦瓦克斯股份有限公司 糖玻璃化的病毒样颗粒
JP2011030455A (ja) * 2009-07-30 2011-02-17 Uha Mikakuto Co Ltd トリプトファン−ヒアルロン酸食品素材及びトリプトファン高含有ペプチド−ヒアルロン酸食品素材並びにそれらの製造方法
JP6431372B2 (ja) 2011-10-25 2018-11-28 プロシーナ バイオサイエンシーズ リミテッド 抗体製剤および方法
EP2801379B1 (en) * 2012-03-27 2017-03-08 Terumo Kabushiki Kaisha Coating composition and medical device
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
US9452138B2 (en) 2012-12-28 2016-09-27 Abbott Cardiovascular Systems Inc. Delivery of biologic therapeutics
US10524489B2 (en) * 2017-07-12 2020-01-07 Zinpro Corporation Method and composition to control rumen release of cobalt to rumen bacteria for making vitamin B12
WO2022163966A1 (ko) * 2021-01-29 2022-08-04 주식회사 티온랩테라퓨틱스 초기 방출 제어된 데포 조성물 및 이의 제조방법
CN117098529A (zh) * 2021-01-29 2023-11-21 天温轮特拉皮踢诗 初期突发释放受控的贮库组合物及其方法
KR102442807B1 (ko) * 2021-01-29 2022-09-15 주식회사 티온랩테라퓨틱스 초기 방출 제어된 데포 조성물 및 이의 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041155A (en) 1974-10-29 1977-08-09 American Home Products Corporation Long acting somatostatin composition
US4278661A (en) * 1979-10-12 1981-07-14 E. I. Du Pont De Nemours And Company Purification of interferon
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPH01287041A (ja) 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
JPH0446200A (ja) * 1990-06-11 1992-02-17 Unitika Ltd 蛋白質固定化材料
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
JP3730667B2 (ja) * 1991-12-27 2006-01-05 武田薬品工業株式会社 注射用組成物
EP0661989B1 (en) 1992-09-21 1997-08-06 PHARMACIA & UPJOHN COMPANY Sustained-release protein formulations
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
AU728949C (en) 1996-12-10 2007-03-29 Purdue Research Foundation Submucosa extracts
IL135186A0 (en) * 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20030064105A1 (en) 2000-08-25 2003-04-03 Myung-Jin Kim Lipophilic-coated microparticle containing a protein drug and formulation comprising same
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
EP1641486B1 (en) 2003-06-10 2012-04-18 LG Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin

Also Published As

Publication number Publication date
CA2595581A1 (en) 2006-08-24
US20080260654A1 (en) 2008-10-23
US8025900B2 (en) 2011-09-27
MY139088A (en) 2009-08-28
BRPI0607000A2 (pt) 2009-07-28
KR100815114B1 (ko) 2008-03-20
IL184558A0 (en) 2007-10-31
ZA200705533B (en) 2008-08-27
EP1850875A1 (en) 2007-11-07
AU2006214913A1 (en) 2006-08-24
TW200640492A (en) 2006-12-01
WO2006088336A1 (en) 2006-08-24
JP2008530204A (ja) 2008-08-07
CN101123988A (zh) 2008-02-13
NZ556584A (en) 2009-09-25
MX2007010131A (es) 2007-09-27
EP1850875A4 (en) 2009-11-11
KR20060093300A (ko) 2006-08-24

Similar Documents

Publication Publication Date Title
AR054739A1 (es) Composicion de liberacion sostenida de droga proteica
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
SMT201300093B (it) Formulazioni di vwf ricombinante liofilizzate
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
NO20074807L (no) Fast farmasoytisk doseringsformulering
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
CR10290A (es) Metodos para reducir la aglomeracion de proteina
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
DK1799748T3 (da) Bionedbrydelige kationiske polymerer
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ATE511393T1 (de) Transdermale fentanylapplikation
IN2015DN03936A (es)
UA100255C2 (uk) Фармацевтична композиція
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
UY32126A (es) Composición farmacéutica sólida
BRPI0516577A (pt) agentes terapêuticos com toxicidade diminuìda
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
BRPI0508610A (pt) derivados de aminoácidos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal